Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland.
Sci Data. 2018 Mar 13;5:180038. doi: 10.1038/sdata.2018.38.
Fever in neutropenia (FN) is the most frequent potentially life threatening complication of chemotherapy for cancer. Prediction of the risk to develop FN during chemotherapy would allow for targeted prophylaxis. This retrospective, single centre cohort study in pediatric patients diagnosed with cancer before 17 years covered two decades, 1993 to 2012. The 583 (73%) of 800 patients diagnosed with cancer who had received chemotherapy were studied here. Data on 2113 observation periods was collected, defined by stable combinations of 11 predefined characteristics potentially associated with FN. They covered 692 years of cumulative chemotherapy exposure time, during which 712 FN episodes were diagnosed, 154 (22%) of them with bacteremia. The risk to develop FN and FN with bacteremia remained stable over time. These data can mainly be used to study FN risks over time and between centers, and to derive or externally validate FN risk prediction rules.
中性粒细胞减少症(FN)发热是癌症化疗最常见的潜在威胁生命的并发症。预测化疗期间 FN 的发生风险可进行靶向预防。这项回顾性、单中心队列研究纳入了 1993 年至 2012 年期间诊断为癌症的 17 岁以下儿科患者。在此研究了 800 名接受化疗的癌症患者中的 583 名(73%)。共收集了 2113 个观察期的数据,这些观察期由 11 个预先定义的特征稳定组合定义,这些特征可能与 FN 相关。它们涵盖了 692 年的累积化疗暴露时间,在此期间诊断出 712 例 FN 发作,其中 154 例(22%)伴有菌血症。FN 和 FN 伴菌血症的发生风险随时间保持稳定。这些数据主要可用于研究 FN 风险随时间和中心的变化,并得出或外部验证 FN 风险预测规则。